{"id":"pacx14","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PACx14 represents a multi-agent chemotherapy combination where paclitaxel (a microtubule stabilizer), doxorubicin (a topoisomerase II inhibitor and intercalating agent), and cyclophosphamide (an alkylating agent) work synergistically to induce cancer cell death. The 'x14' designation likely refers to the number of treatment cycles or a specific dosing schedule. This regimen is designed to maximize cytotoxic effect while being administered in a dose-dense manner to improve efficacy.","oneSentence":"PACx14 is a chemotherapy regimen combining paclitaxel, doxorubicin, and cyclophosphamide administered in a dose-dense schedule for cancer treatment.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:25:21.899Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (likely early-stage or metastatic, under investigation in SWOG trials)"}]},"trialDetails":[{"nctId":"NCT01061437","phase":"PHASE3","title":"S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2009-06","conditions":"Helicobacter Pylori Infection","enrollment":1859}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lansoprazole: Prevacid"],"phase":"phase_3","status":"active","brandName":"PACx14","genericName":"PACx14","companyName":"SWOG Cancer Research Network","companyId":"swog-cancer-research-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PACx14 is a chemotherapy regimen combining paclitaxel, doxorubicin, and cyclophosphamide administered in a dose-dense schedule for cancer treatment. Used for Breast cancer (likely early-stage or metastatic, under investigation in SWOG trials).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}